藥物成份

共有 21692 個藥物成份

Linezolid contains 98.0%~102.0% (as dried basis)

關聯藥證數量
1

Lipase 93 U/LAdenosine triphosphate (ATP) 2.52 mmol/LGlycerol kinase (GK) 4 KIU/LGlycerophosphate oxidase (GPO) 1.1 KIU/L4-Aminoantipyrine 0.71 mmol/L3,5-Dichloro-2-Hydroxybenzenesulfonic acid (DHBS) 1.54 mmol/LHorseradish peroxidase (HPO) 9 KIU/L

關聯藥證數量
1

Lipegfilgrastim

關聯藥證數量
1

Lipid Calibrator is prepared by lyophilizing pooled human sera containing an appropriate amount of lipids.

關聯藥證數量
1

Lipoprotein Lipase, ATP, Glycerol kinase, Glycerol-3-Phosphate-oxidase, 4-aminoantipyrine, 4-chlorophenol, Peroxidase, Mg2+, and Buffer

關聯藥證數量
1

Lipoprotein lipase(LPL)

關聯藥證數量
1

Liquichek ToRCH Plus IgM Control, Positive is prepared from negative human serum based material with mouse monoclonal antibodies conjugated to non-specific human IgM molecules for each analyte tested. The positive control also contains constituents of animal origin and preservatives.

關聯藥證數量
1

Liquid animal sera produced by immunization of rabbits with highly purified human RbP

關聯藥證數量
1

Liquid antinal sera produced by immunization of rabbits with highly purified human haptoglobin.

關聯藥證數量
1

Liquid, ready-for-use control materials based on juman serum with assayed values for all important serum proteins in the normal and abnormal range.

關聯藥證數量
1

Liquimmune® is a liquid stable control material prepared from human serum. Analyte levels are adjusted with various pure chemicals and preparations from human tissue or body fluids. Prostate specific antigen is from human seminal fluid, alpha-fetoprotein is from human cord serum and carcinoembryonic antigen is from hepatic metastases of human colon adenocarcinoma. Preservatives and stabilizers are added to maintain product integrity.

關聯藥證數量
1

Lisinopril (2S)-1-[(2S)-6-Amino-2-[[(1S)-1-carboxy-3-phenylpropyl]-amino]hexanoyl]pyrrolidine-2-carboxylic acid dihydrate. Content: 98.5 per cent to 101.5 per cent (anhydrous substance).

關聯藥證數量
1

Lisinopril Dihydrate(Anhydride Process) contains not less than 98.5% and not more than 101.5% of C21H31N3O5．2H2O), calculated on the anhydrous substance.

關聯藥證數量
1

Lisinopril contains not less than 98.0% and not more than 102.0% of C21H31N3O5, calculated on the anhydrous basis.

關聯藥證數量
1

Lite reagent: T. gondii antigen (~1.05μg/mL) complexed with an anti-p30 monoclonal labeled with acridinium ester in protein buffer with surfactant and preservatives\nSolid phase: anti-human IgGFc monoclonal antibody (~0.3 mg/mL) covalently coupled to paramagnetic particles in protein buffer with surfactant and preservatives\nCalibrators: processed human plasma positive for toxoplasma IgG antibodies with preservatives\nControls: processed human plasma negative and positive for toxoplasma IgG antibodies with preservatives\n

關聯藥證數量
1

Lite reagent: T. gondii antigen (~3μg/mL) complexed with an anti-p30 monoclonal labeled with acridinium ester in protein buffer with surfactant and preservatives\nSolid phase: anti-human IgMμ monoclonal antibody (~24 μg/mL) covalently coupled to paramagnetic particles in protein buffer with surfactant and preservatives\nCalibrators: processed human plasma positive for toxoplasma IgM antibodies with preservatives\nControls: processed human plasma negative and positive for toxoplasma IgM antibodies with preservatives\n

關聯藥證數量
1

Lite reagent: acridinium ester-labeled phenobarbital (~302 pg/mL) in buffer with preservatives\nSolid phase: monoclonal mouse anti-phenobarbital antibody (~4μg/mL) covalently coupled to paramagnetic particles in buffer with preservatives\nReleasing agent: 0.2M CAPS buffer preservatives\nCalibrator: low and high levels of phenobarbital in human plasma with sodium azide (<0.1%) and preservatives\n \n

關聯藥證數量
1

Lite reagent: gentamicin derivative labeled with acridinium ester (~0.46 ng/mL) in phosphate buffer with BSA, sodium azide (<0.1%), and preservatives\nSolid phase: monoclonal mouse anti-gentamicin antibody (~20μg/mL) covalently coupled to paramagnetic particles in phosphate buffered saline with BSA, sodium azide (<0.1%), and preservatives\nProbe Wash 2: 0.2N hydrochloric acid\nCalibrator: after reconstitution, low and high levels of gentamicin in human serum with sodium azide (<0.1%) \n

關聯藥證數量
1

Lite reagent: inactivated rubella virus antigen (strain HPV77) (~0.20μg/mL) labeled with acridinium ester in protein buffer with surfactant and preservatives\nSolid phase: anti-human IgGFc monoclonal antibody (~0.15 mg/mL) covalently coupled to paramagnetic particles in protein buffer with preservatives\nCalibrators: processed human plasma positive for rubella IgG antibodies with preservatives\nControls: processed human plasma negative and positive for rubella IgG antibodies with preservatives\n

關聯藥證數量
1

Lite reagent: inactivated rubella virus antigen (strain HPV77) (~0.27μg/mL) labeled with acridinium ester in buffer with preservatives\nSolid phase: anti-human IgMμ monoclonal antibody (~0.14 mg/mL) covalently coupled to paramagnetic particles in buffer with preservatives\nCalibrators: processed human plasma positive for rubella IgM antibodies with preservatives\nControls: processed human plasma negative and positive for rubella IgM antibodies with preservatives\n \n

關聯藥證數量
1

Lite reagent: monoclonal mouse anti-digitoxin antibody (~60 ng/mL) labeled with acridinium ester in buffer with protein stabilizers, sodium azide (<0.1%), and preservatives\nSolid phase: digoxin (~3.4μg/mL) covalently coupled to paramagnetic particles in buffer with protein stabilizers, sodium azide (<0.1%), and preservatives\n

關聯藥證數量
1

Lite reagent: monoclonal mouse anti-human BNP F(ab’)2 fragment antibody (~0.025μg/mL) labeled with acridinium ester in buffer with bovine gamma globulin, mouse gamma globulin and preservatives\nSolid phase: monoclonal mouse anti-human BNP antibody (~1.25μg/mL) in bovine gamma globulin, mouse gamma globulin and preservatives\nCalibrator: after reconstitution, low or high levels of synthetic human BNP in lyophilized buffered sodium caseinate with sodium azide (<0.1%)\nQC: various levels of synthetic human BNP in lyophilized buffered sodium caseinate with sodium azide (<0.1%)\n

關聯藥證數量
1

Lite reagent: monoclonal mouse anti-human HER-2/neu antibody (~1.8μg/mL) labeled with acridinium ester in phosphate buffer with bovine serum albumin and sodium azide (<0.1%)Solid phase: monoclonal mouse anti-fluorescein antibody (~30μg/mL) coupled to paramagnetic particles in phosphate buffer with bovine serum albumin and sodium azide (<0.1%)Fluorescein conjugate reagent: monoclonal mouse anti-human HER-2/neu antibody (~7.0μg/mL) labeled with fluorescein in PIPES buffer with bovine serum albumin and sodium azide (<0.1%)Calibrator: low or high levels of HER-2/neu in bovine serum with sodium azide (<0.1%)QC: low and high levels of HER-2/neu in bovine serum with sodium azide (<0.1%)

關聯藥證數量
1

Lite reagent: polyclonal goat anti-PSA antibody (~77 ng/mL) labeled with acridinium ester in buffered saline with bovine serum albumin and preservatives \nSolid phase: monoclonal mouse anti-PSA antibody (~25μg/mL) covalently coupled to paramagnetic particles in buffered saline with bovine serum albumin and preservatives\nPretreatment: free-PSA-specific monoclonal mouse anti-PSA antibody (~50μg/mL) in buffered saline with bovine serum albumin and preservatives \nCalibrator: after reconstitution, low or high levels of complexed PSA in goat serum with sodium azide (<0.1%) and preservatives \nQC: after reconstitution, various levels of complexed PSA in goat serum with sodium azide (<0.1%) and preservatives \n

關聯藥證數量
1

Lite reagent: theophylline labeled with acridinium ester (~0.3 ng/mL) in buffered saline with bovine serum albumin and sodium azide (<0.1%)\nSolid phase: monoclonal mouse anti-theophylline antibody (~3 μg/mL) bound to monoclonal mouse capture antibody (~14μg/mL) covalently coupled to paramagnetic particles in buffered saline with bovine serum albumin and sodium azide (<0.1%) \nCalibrators: low or high levels of theophylline in human plasma with sodium azide (0.2% after reconstitution), preservatives, and protein stabilizers\n

關聯藥證數量
1

Lite reagent: tobramycin (~0.16 ng/mL) labeled with acridinium ester in buffered saline with sodium azide (<0.1%), and preservatives\nSolid phase: monoclonal mouse anti-tobramycin antibody (~16μg/mL) covalently coupled to paramagnetic particles in buffered saline with sodium azide (<0.1%), and preservatives\n

關聯藥證數量
1

Lite reagent: valproic acid (~0.2 ng/mL) labeled with acridinium ester in phosphate buffered saline with bovine serum albumin, bovine gamma globulin, and preservatives\nSolid phase: monoclonal mouse anti-valproic acid antibody (~6.7μg/mL) coupled to paramagnetic particles in phosphate buffered saline with bovine serum albumin, bovine gamma globulin, and preservatives\nCalibrator: after reconstitution, low or high levels of valproic acid in human plasma with sodium azide (<0.1%) and preservatives\n

關聯藥證數量
1

Lite reagent: vancomycin (~6 ng/mL) coupled to bovine serum albumin labeled with acridinium ester in buffered saline with sodium azide (<0.1%) and preservatives\nSolid phase: monoclonal mouse anti-vancomycin (~6.7 μg/mL) covalently coupled to paramagnetic particles in buffered saline with sodium azide (<0.1%) and preservatives\nCalibrators: after reconstitution, low or high levels of vancomycin in human serum with sodium azide (<0.1%) and preservatives\n

關聯藥證數量
1

Lithium Carbonate contains not less than 98.0% and not more than 102.0% of lithium carbonate(Li2CO3), calculated on the dried basis.

關聯藥證數量
1

Lithium Carbonate contains not less than 99.0% w/w of Li2CO3, calculated on dried basis.

關聯藥證數量
1

Lithium Heparin

關聯藥證數量
1

Lithium carbonate contains not less than 98.5% and not more than 100.5% of Li2CO3, calculated on the dried basis.

關聯藥證數量
1

Lius A Reagent:\n0.05% Methylene Blue, 0.18% Eosin Yellowish in Methanol\nLius B Reagent:\n0.14% Methylene Blue 0.14% Azure I in Phosphate buffer solution

關聯藥證數量
1

Live attenuated measles virus (Schwarz strain)

關聯藥證數量
1

Live attenuated mumps virus (RIT 4385 strain, derived from Jeryl Lynn strain)

關聯藥證數量
1

Live attenuated rubella virus (Wistar RA 27/3 strain)

關聯藥證數量
1

Live attenuated varicella virus (OKA strain)

關聯藥證數量
1

Live, attenuated, recombinant Japanese encephalitis virus

關聯藥證數量
1

Loperamide HCl contains 99% to 101% of C29H33ClN2O2 HCl

關聯藥證數量
1

Loperamide Hydrochloride contains not less than 98.0 percent and not more than 102.0 percent of C29H33ClN2O2‧HCl, calculated on the dried basis.

關聯藥證數量
1

Loratadine contains 98.5% to 101.5% (dried substance).

關聯藥證數量
1

Loratadine contains not less than 98.5 percent and not more than 101.0 percent of C22H23ClN2O2, calculated on dried basis.

關聯藥證數量
1

Loratadine contains not less than 98.5% not more than 101.0% of C22H23CIN2O2, calculated on the dried basis.

關聯藥證數量
1

Loratadine contents not less than 98.5% and not more than 101.0% of C22H23CIN2O2, calculated on the dried basis.

關聯藥證數量
1

Lorazepam contains not less than 98.5% and not more than 102.0% of C15H10Cl2N2O2, calculated on the dried basis.

關聯藥證數量
1

Lorazepam contains not less than 98.5% and not more than 102.0%the equivalent of C15H10Cl2N2O2

關聯藥證數量
1

Lorazepam contains not less than 98.5% and not more than the equivalent of 101.0% of C15H10CI2N2O2, calculated with reference to the dried substance.

關聯藥證數量
1

Lorcaserin HCl hemihydrate

關聯藥證數量
1

Lorcaserin hydrochloride hemihydrate (Form-III) Contains 98.0% ~ 102.0% of C11H15Cl2N‧0.5H2O

關聯藥證數量
1

Lornoxicam contains not less than 98.0% and not more than 102.0% of C13H10ClN3O4S2 calculated on the dried basis.

關聯藥證數量
1

Losartan Potassium Content:98.5 percent to 101.5 percent (dried substance).

關聯藥證數量
1

Losartan Potassium contains not less than 98.0% and not more than 102.0% of C22H22N6OClK, calculated with reference to the dried substance.

關聯藥證數量
1

Losartan Potassium contains not less than 98.5% and not more than 101.0% of C22H22CIKN6O calculated on the anhydrous, solvent-free basis

關聯藥證數量
1

Losartan Potassium contains not less than 98.5% and not more than 101.0% of C22H22ClKN6O calculated on anhydrous basis.

關聯藥證數量
1

Losartan Potassium contains not less than 98.5% and not more than 101.0% of C22H22ClKN6O calculated on the anhydrous, solvent-free basis.

關聯藥證數量
1

Losartan Potassium contains not less than 98.5% and not more than 101.0% of C22H22ClKN6O, calculated on the anhydrous basis.

關聯藥證數量
1

Losartan Potassium contains not less than 98.5% and not more than 101.0% of C22H22ClKN6O, calculated on the anhydrous, solvent-free basis.

關聯藥證數量
1

Losartan potassium contains not less than 98.5% and not more than of 101.0% of C22H22ClKN6O calculated on the anhydrous, solvent -free basis.

關聯藥證數量
1

Lovastatin contains not less than 98.5 and more than 101.0% of C24H36O5, calculated on the dried basis.

關聯藥證數量
1

Lovastatin contains not less than 98.5% and not more than 101.0% of C24H36O5, calculated on the dried basis.

關聯藥證數量
1

Low D-D Control: 5 vials×1 mL of a lyophilized solution of D-Dimer partially purified from human fibrin digested with human plasmin containing bovine serum albumin. \nHigh D-D Control: 5 vials×1 mL of a lyophilized solution of D-Dimer partially purified from human fibrin digested with human plasmin containing bovine serum albumin. \n

關聯藥證數量
1

Low Specific Gravity Calibrator : Contains an aqueous sodium chloride solution with a specific gravity of 1.010 g/mL.\nHigh Specific Gravity Calibrator : Contains an aqueous sodium chloride solution with a specific gravity of 1.025 g/mL.\nLevel 1 Specific Gravity Control : Contains an aqueous sodium chloride solution with a specific gravity of 1.015 g/mL.\nLevel 2 Specific Gravity Control : Contains an aqueous sodium chloride solution with a specific gravity of 1.030 g/mL.

關聯藥證數量
1

Low control solution:\n0.04% Glucose, 0.01% Beta-hydroxybutyrate, and 99.95% Non-reactive ingredients\nHigh control solution:\n0.22% Glucose, 0.04% Beta-hydroxybutyrate, and 99.74% Non-reactive ingredients

關聯藥證數量
1

Low or high levels of estradol in human plasma with sodium azide (0.1%)and preservatives.

關聯藥證數量
1

Low-molecular-weight sodium hyaluronate

關聯藥證數量
1

Low-protein reagents prepared from human/mouse heterohybridoma cell lines secreting human IgM antibodies: clone C2

關聯藥證數量
1

Low-protein reagents prepared from human/mouse heterohybridoma cell secreting human IgM antibodies：clone MS16\n0.1% sodium azide, bovine albumin, sodium chloride, protein macromolecules.

關聯藥證數量
1

Loxoprofen Sodium Dihydrate contains not less than 98.5% of C15H17NaO3．2H2O Calculated on the anhydrous basis.

關聯藥證數量
1

Loxoprofen Sodium Hydrate contains: not less than 98.5 percent (anhydrous basis)

關聯藥證數量
1

Lp(a) Latex“Daiichi”Buffer Solution: glycine buffer (pH9.0) 50mmol/L\nLp(a) Latex“Daiichi”Latex Reagent: antihuman Lp(a) mouse monoclonal antibody-coated latex 1.6mg/mL\nLp(a) Latex Standard Serum H: Human Serum\nLp(a) Latex Standard Serum L: Human Serum\nLp(a) Latex Standard Serum M: Human Serum\nLp(a) Control Serum“Daiichi”High: Human Serum\nLp(a) Control Serum“Daiichi”Low: Human Serum

關聯藥證數量
1

Lurbinectedin

關聯藥證數量
1

Lyophilised human serum containing creatine kinase-MB isoenzyme.

關聯藥證數量
1

Lyophilized G-6-PDH (microbial) in a human red cell hemolysate base with stabilizers and preservatives.

關聯藥證數量
1

Lyophilized Human Serum 1 x 1 mL\nDiluent (saline solution) 2 x 2 mL

關聯藥證數量
1

Lyophilized bovine thrombin;\ncontains HEPES buffer, calcium chloride, and stabilizers.

關聯藥證數量
1

Lyophilized extract of rabbit brain with buffer, stabilizers and calcium chloride.

關聯藥證數量
1

Lyophilized human plasma that has been depleted of factor VIII; contains stabilizers.

關聯藥證數量
1

Lyophilized human plasma that has been depleted of the specific factor; contains stabilizers.

關聯藥證數量
1

Lyophilized human plasmas with a residual Factor VIII, IX, XI or XII of ≦1%. Fibrinogen is present in a quantity of at least 1 g/L and the remaining extrinsic pathway factors are present in an activity greater than 40% of the norm.

關聯藥證數量
1

Lyophilized human serum with therapeutic drug constituents, 0.51 g/vial

關聯藥證數量
1

Lyophilized human serum with:\nAmylase source: porcine pancreas\nCK source: rabbit skeletal muscle\nGGT source: porcine kidney\nGOT source: porcine heart\nGPT source: porcine heart

關聯藥證數量
1

Lyophilized human serum, 0.17 g/vial

關聯藥證數量
1

Lyophilized human serum, 0.26 g/vial

關聯藥證數量
1

Lyophilized human serum, 0.85g/vial

關聯藥證數量
1

Lyophilized pooled-fresh by human serum.

關聯藥證數量
1

Lyophilized preparation of 1-epinephrine bitartarate with stabilizers.

關聯藥證數量
1

Lyophilized rabbit brain extract with buffer, stabilizers and calcium chloride\n50220 Thromboplastin, dried, 4 mL\n50250 Thromboplastin, dried, 10 mL\n50221 Thromboplastin-S, dried, 4 mL\n50251 Thromboplastin-S, dried, 10 mL\n\n\n\n

關聯藥證數量
1

Lyophilized thrombin from human plasma.

關聯藥證數量
1

Lyophilized universal serum based on human serum with assayed values for all important coponents of human serum preferably in the abnormal range.

關聯藥證數量
1

Lyophilized, buffer human plasma containing protein stabilizers with similar characteristics to fresh normal plasma.

關聯藥證數量
1

Lyophilized, buffer plasma in which Factor II, VII, IX, and X have been selectively and partially removed.

關聯藥證數量
1

Lyophilized, buffered human plasma containing protein stabilizers in which Factor II, VII, IX, and X have been selectively reduced.

關聯藥證數量
1

Lyophilized, buffered normal plasma containing proteins stabilizers.

關聯藥證數量
1

Lyophilized, buffered plasma containing protein stabilizers and optimal levels of hemostasis proteins.

關聯藥證數量
1

Lyophilizer form from human serum. Stabilizers have been added.

關聯藥證數量
1

Lysine Hydrochloride contains not less than 98.5% and not more than 101.5% of C6H14N2O2？HCl, as L-lysine Hydrochloride, calculated on the anhydrous basis.

關聯藥證數量
1

Lysing Solution \nBuffered surfactant

關聯藥證數量
1

Lysis solution, Wash 1 solution, Wash 2 solution, RNA Elution Solution, Preclear Columns, Preclear Columns, TCEP, Proteinase K Solution, Proteinase K Solution.

關聯藥證數量
1

Lysis solution, Wash 1 solution, Wash 2 solution, RNA Elution Solution.

關聯藥證數量
1

Lysis solution、Wash 1 solution、Wash 2 solution、RNA Elution Solution、Preclear Columns、Preclear Columns、Proteinase K Solution、Proteinase K Solution、RBC Lysis solution

關聯藥證數量
1